Viatris Inc
VTRSNasdaq · SIC 2834
$17.29
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +97.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$20.3B
Enterprise Value
$32.9B
P/E
—
P/S
1.4
P/B
1.4
EV/EBITDA
11.1
PEG
—
FCF Yield
8.8%
Dividend Yield
2.8%
Revenue (TTM)
$14.6B
Net Income (TTM)
—
Free Cash Flow (TTM)
$1.8B
Gross Margin
34.4%
Operating Margin
1.0%
Net Margin
—
ROE
—
ROIC
0.4%
Debt / Equity
1.0
Net Cash
-$12.5B
Return 1Y
+93.9%
Company profile
Viatris Inc. operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
- CEO
- Michael Goettler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 37,000
- Headquarters
- Pennsylvania
- Website
- viatris.com
Management & directors
- Campbell PaulSee Remarks
- Le Goff CorinneChief Commercial Officer
- Enrietti AndrewSee Remarks
- Mistras TheodoraChief Financial Officer
- Smith Scott AndrewChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-06
VTRS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.5B↑ +8.1%
Diluted EPS$0.15↓ -105.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.9B | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Gross profit | $3.8B | $5.6B | $6.5B | $6.4B | $5.6B | $5.0B |
| Operating income | -$210.8M | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B |
| Net income | — | — | — | — | — | — |
| Diluted EPS | -$1.11 | -$1.05 | $1.71 | $0.05 | -$0.53 | -$3.00 |
| Operating cash flow | $1.2B | $3.0B | $3.0B | $2.9B | $2.3B | $2.3B |
| Free cash flow | $988.8M | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| Gross margin | 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% |
| Operating margin | -1.8% | -0.2% | 9.9% | 5.0% | 0.1% | -18.6% |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8B | $3.8B | $3.5B | $3.3B | $3.6B | $3.8B | $3.7B | $3.5B |
| Gross profit | $1.4B | $1.5B | $1.2B | $1.2B | $1.3B | $1.4B | $1.1B | $1.2B |
| Operating income | -$239.9M | $225.9M | -$179.8M | -$2.9B | $233.0M | $178.8M | -$192.7M | -$79.7M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$0.27 | $0.08 | -$0.43 | -$2.55 | $0.00 | -$0.11 | -$0.34 | $0.15 |
| Operating cash flow | $379.1M | $826.5M | $482.7M | $535.5M | $219.7M | $744.9M | $815.8M | $388.3M |
| Free cash flow | $320.3M | $749.5M | $342.3M | $492.9M | $166.8M | $658.1M | $619.3M | $348.4M |
| Gross margin | 38.1% | 38.9% | 34.4% | 35.7% | 37.2% | 36.5% | 31.0% | 32.9% |
| Operating margin | -6.3% | 6.0% | -5.1% | -88.6% | 6.5% | 4.8% | -5.2% | -2.3% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 9, 2026
- 11d agoVTRS or DHR: Which Is the Better Value Stock Right Now?finance.yahoo.com
- 11d agoSystemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsightfinance.yahoo.com
- 11d agoShould Value Investors Buy Viatris (VTRS) Stock?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | Campbell Paul· See Remarks | Sale | 50,076 | $16.17 | $809,784.00 | filing |
| 2026-04-15 | Le Goff Corinne· Chief Commercial Officer | Tax withholding | 17,450 | $13.86 | $241,857.00 | filing |
| 2026-04-15 | Le Goff Corinne· Chief Commercial Officer | Tax withholding | 1,617 | $13.86 | $22,411.62 | filing |
| 2026-04-15 | Le Goff Corinne· Chief Commercial Officer | Option exercise | 39,344 | $0.00 | $0.00 | filing |
| 2026-04-15 | Le Goff Corinne· Chief Commercial Officer | Option exercise | 3,644 | $0.00 | $0.00 | filing |
| 2026-03-23 | Campbell Paul· See Remarks | Sale | 21,350 | $13.28 | $283,538.68 | filing |
| 2026-03-06 | Smith Scott Andrew· Chief Executive Officer | Tax withholding | 48,999 | $14.16 | $693,825.84 | filing |
| 2026-03-06 | Mistras Theodora· Chief Financial Officer | Tax withholding | 23,067 | $14.16 | $326,628.72 | filing |
| 2026-03-06 | Le Goff Corinne· Chief Commercial Officer | Tax withholding | 19,588 | $14.16 | $277,366.08 | filing |
| 2026-03-06 | Campbell Paul· See Remarks | Tax withholding | 12,088 | $14.16 | $171,166.08 | filing |
| 2026-03-06 | Enrietti Andrew· See Remarks | Tax withholding | 8,337 | $14.16 | $118,051.92 | filing |
| 2026-03-06 | Smith Scott Andrew· Chief Executive Officer | Tax withholding | 2,433 | $14.16 | $34,451.28 | filing |
| 2026-03-06 | Groothuis Leo Frans | Tax withholding | 1,243 | $14.16 | $17,600.88 | filing |
| 2026-03-06 | Mistras Theodora· Chief Financial Officer | Tax withholding | 1,146 | $14.16 | $16,227.36 | filing |
| 2026-03-06 | Le Goff Corinne· Chief Commercial Officer | Tax withholding | 973 | $14.16 | $13,777.68 | filing |
| 2026-03-06 | Campbell Paul· See Remarks | Tax withholding | 601 | $14.16 | $8,510.16 | filing |
| 2026-03-06 | Enrietti Andrew· See Remarks | Tax withholding | 415 | $14.16 | $5,876.40 | filing |
| 2026-03-06 | Groothuis Leo Frans | Tax withholding | 62 | $14.16 | $877.92 | filing |
| 2026-03-06 | HIGGINS MELINA E | Option exercise | 1,175 | $0.00 | $0.00 | filing |
| 2026-03-06 | Groothuis Leo Frans | Option exercise | 23,660 | $0.00 | $0.00 | filing |
| 2026-03-06 | Groothuis Leo Frans | Option exercise | 1,175 | $0.00 | $0.00 | filing |
| 2026-03-06 | KILTS JAMES M | Option exercise | 23,660 | $0.00 | $0.00 | filing |
| 2026-03-06 | KILTS JAMES M | Option exercise | 1,175 | $0.00 | $0.00 | filing |
| 2026-03-06 | Lyons Dillon JoEllen | Option exercise | 23,660 | $0.00 | $0.00 | filing |
| 2026-03-06 | Lyons Dillon JoEllen | Option exercise | 1,175 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.